Ico Therapeutics (ICOTF) 0.0700 $ICOTF
iCo Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 29, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" .
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
CNW Group - Tue Aug 19, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp 
drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.
iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:
Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public.
iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC" , thus providing the Company with DTC eligibility.
IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units" at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant.
IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company" (TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units" at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share" for a period of five years following the closing of the Offering.
iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
PR Newswire - Tue Jan 21, 4:00PM CST
iCo Therapeutics Inc. ("iCo" or the "Company" (TSXV: ICO) (OTCQX: ICOTF) announced today that it has undertaken an overnight marketed public offering (the "Offering" of units (the "Units" , comprised of common shares of the Company and common share purchase warrants (a "Warrant" . The Offering is to be effected in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to iCo's base shelf prospectus dated July 3, 2012 and elsewhere on a private placement basis. Prior to the Offering, iCo had 67,811,230 common shares issued and outstanding. The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market.
iCo Therapeutics Begins Trading on the OTCQX Marketplace
CNW Group - Fri Dec 20, 6:00AM CST
iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on OTCQX International, a segment of the OTCQX marketplace in the U.S., under the symbol "ICOTF." iCo's common shares will also continue to trade on the TSX Venture Exchange under the symbol "ICO".
iCo Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 29, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" . iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
CNW Group - Tue Aug 19, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy. iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity. Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee. iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows: Immune CEO Announces New Operational Leadership Team
GlobeNewswire - Wed Apr 02, 1:30AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today the addition of two new senior members to its management team.
Immune Pharmaceuticals Announces $11.7 Million Private Placement Financing
GlobeNewswire - Sun Mar 09, 11:01PM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) announced today that it has entered into a definitive agreement with investors for the sale of $11.7 million of preferred stock and warrants in a private placement transaction (expected to result in approximately $11 million in net proceeds to Immune, after the subtraction of transaction fees and expenses). Additional details regarding the material terms of the transaction, which is expected to close on March 11, 2014, will be disclosed in a Current Report on Form 8-K expected to be filed this day.
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study
CNW Group - Wed Mar 05, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month twelve. Next steps include data queries and subsequent data lock. Once these activities are complete, the results will be analyzed and top-line results will be made public. iCo Therapeutics Announces DTC Approval
PR Newswire - Tue Feb 25, 12:15PM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that its United States trading symbol ICOTF has received approval from The Depository Trust Company (the "DTC" , thus providing the Company with DTC eligibility. IIROC Trade Resumption / L'OCRCVM permet la reprise de la négociation - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 9:20AM CST
Trading resumes in / Reprise des negociations pour:
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing
PR Newswire - Mon Jan 27, 9:03AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) announced today that it has closed its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo issued 16,206,483 units of the Company ("Units" at a price of $0.4165 per Unit for aggregate gross proceeds of C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarters of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one Common Share for a period of five years following the date of issuance of the Warrant. IIROC Trading Halt / Suspension de la négociation par l'OCRCVM - ICO Therapeutics Inc., ICO
Marketwire Canada - Mon Jan 27, 8:43AM CST
The following issues have been halted by IIROC / L'OCRCVM a suspendu la negociation des titres suivants :
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing
PR Newswire - Wed Jan 22, 7:42AM CST
iCo Therapeutics Inc. ("iCo" or the "Company"
(TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today that the Company has priced its previously announced overnight marketed offering of equity securities (the "Offering" . Pursuant to the Offering, iCo will issue an aggregate of up to 16,206,483 units of the Company ("Units" at a price of C$0.4165 per Unit for aggregate gross proceeds of approximately C$6.75 million. Each Unit is comprised of one common share of the Company (a "Common Share" and three-quarter of one common share purchase warrant (each whole warrant, a "Warrant" . Each Warrant is exercisable at a price of C$0.539 and entitles the holder thereof to acquire one common share of the Company (a "Warrant Share" for a period of five years following the closing of the Offering. iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering
PR Newswire - Tue Jan 21, 4:00PM CST
iCo Therapeutics Inc. ("iCo" or the "Company"
(TSXV: ICO) (OTCQX: ICOTF) announced today that it has undertaken an overnight marketed public offering (the "Offering" of units (the "Units" , comprised of common shares of the Company and common share purchase warrants (a "Warrant" . The Offering is to be effected in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to iCo's base shelf prospectus dated July 3, 2012 and elsewhere on a private placement basis. Prior to the Offering, iCo had 67,811,230 common shares issued and outstanding. The number of Units to be distributed under the Offering, the price of each Unit and the exercise price of each Warrant will be determined in the context of the market. iCo Therapeutics Begins Trading on the OTCQX Marketplace
CNW Group - Fri Dec 20, 6:00AM CST
iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on OTCQX International, a segment of the OTCQX marketplace in the U.S., under the symbol "ICOTF." iCo's common shares will also continue to trade on the TSX Venture Exchange under the symbol "ICO".
